Baxter International INC 8-K filings

Baxter International Inc. announced the resignation of its Interim Chief Financial Officer, Anita Zielinski, effective September 15, 2026.

Baxter International Inc. has commenced cash tender offers to purchase up to $500 million of its outstanding senior notes, aiming to optimize its debt structure.

Baxter International Inc. announced second-quarter 2026 results, exceeding expectations with sales growth and raising its full-year financial outlook.

Baxter International Inc. is updating its reporting segments to align with its new operating model, effective from the second quarter of 2026, with no impact on previously reported consolidated financial statements.

Baxter International Inc. announced first-quarter 2026 results, with sales from continuing operations reaching $2.7 billion, and reiterated its full-year financial outlook.

Baxter International Inc. provided an update on its leadership transitions, strategic initiatives, 2025 financial performance, and corporate governance in a recent stockholder engagement presentation.

Baxter International Inc. announced the departure of CFO Joel Grade, effective March 16, 2026, and the immediate appointment of Anita Zielinski as interim CFO.

Baxter International reported fourth-quarter 2025 sales growth but missed expectations, alongside a significant board refreshment and a lowered 2026 financial outlook.

Baxter International Inc. announced the final settlement of its cash tender offers, repurchasing over $1 billion in senior unsecured notes due 2026 and 2027.

Baxter International Inc. successfully issued $2 billion in new senior notes and announced early tender results for existing debt, signaling a strategic refinancing initiative.

Baxter International Inc. has amended its credit agreement to temporarily increase its maximum net leverage ratio, providing greater financial flexibility.

Baxter International Inc. announced an increase in the maximum purchase price for its cash tender offer for 1.915% senior unsecured notes due 2027 from $300 million to $600 million.

Baxter International Inc. announced cash tender offers for its 2026 and a portion of its 2027 senior unsecured notes, aiming to refinance debt with new notes.

Baxter International Inc. announced the resignation of Alok Sonig, Executive Vice President and Group President, Pharmaceuticals, effective December 1, 2025.

Baxter International Inc. reported third-quarter 2025 sales of $2.84 billion, a 5% increase, with adjusted diluted EPS of $0.69, as new CEO Andrew Hider outlines a focus on continuous improvement.

Baxter International Inc. announced the resignation of its Chief Operating Officer, Heather Knight, effective October 29, 2025, with CEO Andrew Hider assuming her interim group president responsibilities.

Baxter International Inc. announced second-quarter 2025 financial results that met previously issued guidance, alongside the appointment of Andrew Hider as its new President and CEO.

Baxter International Inc. announced the appointment of Andrew Hider as its new President and Chief Executive Officer, effective no later than September 3, 2025, with interim CEO Brent Shafer transitioning to non-executive Chair of the Board.

Baxter International Inc. has successfully amended and restated its credit agreements, securing a new $2.2 billion revolving credit facility with an option to expand to $3.3 billion and refinancing its $645 million term loan, extending maturity dates and optimizing its debt structure.

Baxter International Inc. held its 2025 Annual Meeting on May 6, 2025, with shareholders electing directors, approving executive compensation, and ratifying the appointment of PricewaterhouseCoopers LLP as the company's independent auditor.

Baxter International reports a strong first quarter in 2025, exceeding sales and earnings guidance, and subsequently increasing the lower end of its full-year adjusted EPS outlook.

Baxter International announces leadership changes, including an interim CEO appointment, and highlights strategic actions following the divestiture of its Kidney Care business.

Baxter International Inc. announces positive fourth-quarter and full-year 2024 results, surpassing previous guidance, and completes the sale of its Kidney Care business.

Baxter International finalizes the sale of its Kidney Care business (Vantive) to Carlyle Group for $3.71 billion and releases pro forma financial information reflecting the transaction.

Baxter International has announced the retirement of its CEO, Jos Almeida, and the appointment of Brent Shafer as interim CEO, along with other key leadership changes.

Baxter International finalized the sale of its Kidney Care business to Spruce Bidco for approximately $3.71 billion in net, pre-tax cash proceeds, after adjustments.

Baxter International Inc. has appointed Anita Zielinski as its Senior Vice President, Chief Accounting Officer and Controller, effective February 21, 2025.

Baxter International Inc. has amended its bylaws to revise voting standards, enhance stockholder proposal procedures, and establish exclusive forums for legal claims.

Baxter International Inc. reports the resignation of director Peter M. Wilver, effective December 31, 2024, and the appointment of Jeffrey A. Craig as the new Audit Committee chairperson.

Baxter International Inc. reported strong third-quarter 2024 results, exceeding earnings guidance, while also managing the impact of Hurricane Helene and progressing with the sale of its Kidney Care business.